Recursion Pharmaceuticals RXRX · Forecast & Analysis
- Recursion placed fourth among more than 270 participants in an AI drug-discovery benchmark, a modest knock to its competitive standing.
- The overall picture is firmly bearish, and that lean holds across the near-, medium- and longer-term views.
- With no fresh technical signals on the charts, the bearish case rests on news rather than price behaviour.
- High-impact US inflation data due in three days is the next macro event likely to move the whole market, this stock included.
News situation · 1 items / 30 D
1 of 1 straight from the issuer or regulator
Outlook for Recursion Pharmaceuticals
Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.
What drives it
- The fourth-place finish in the OpenADMET CYP Direct Inhibition Blind Challenge, announced November 6, behind Inductive and NVIDIA.
- The result feeds doubt about Recursion's edge in AI-driven ADMET prediction against specialised competitors.
What argues against it
- A benchmark placement is a one-off result with no stated revenue or guidance impact, so it may fade without lasting price effect.
- Fourth place among more than 270 ranked participants is still near the top of a large field, which limits the damage to the competitive story.
- US CPI releases due in three days are high-impact macro events that could move the whole market, this stock included, in either direction.
- US initial jobless claims follow five days later and add another window of macro-driven volatility.
Coming up
- US: Jobless claims
- US: EIA Crude Oil Stocks Change
- US: Producer prices · expected 0.4%, previous 0.7%
Economic data for RXRX
Full calendarRecently released
- TodayUSDCore CPI y/y●●●Forecast 2.8%Previous 2.6%
- TodayUSDCPI y/y●●●Forecast 4.2%Previous 3.7%
- TodayUSDCore CPI m/m●●●Forecast 0.2%Previous 0.3%
- TodayUSDCPI●●●Forecast 338.683Previous 336.298
- TodayUSDCPI m/m●●●Forecast 0.5%Previous 0.6%
- TodayUSDCore CPI n.s.a. m/m●●●Previous 0.4%
- TodayUSDCore CPI●●●Forecast 339.796Previous 338.896
Coming up
- November 12, 2026USDInitial Jobless Claims●●●in 1 day
- November 12, 2026USDEIA Crude Oil Stocks Change●●●in 1 day
- November 13, 2026USDCore PPI m/m●●●Forecast 0.4%Previous 0.7%in 2 days
- November 13, 2026USDPPI m/m●●●Forecast 0.4%Previous 1.3%in 2 days
- November 17, 2026USDCore Retail Sales m/m●●●Forecast 0.7%Previous 0.9%in 6 days
- November 17, 2026USDRetail Sales m/m●●●Forecast 0.3%Previous 0.8%in 6 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
Both worlds over time
Technical and news signals of the last 90 days on one timeline.
What is being reported about RXRX
In-depth analysis of Recursion Pharmaceuticals
AI-generated · as of November 7, 2026
The bearish read on Recursion is firm and consistent across every time horizon, though the concrete evidence behind it is thinner than the strength of the signal. The one fresh item is yesterday's OpenADMET CYP Direct Inhibition Blind Challenge, where Recursion placed fourth among more than 270 eligible participants, behind the winner Inductive and third-place NVIDIA.
Read full analysis
For a company whose story rests on being at the front of AI-driven drug discovery, a finish behind specialised rivals in an ADMET prediction benchmark is a small but real knock to its competitive narrative, and news sentiment points bearish. The mitigating context matters too: a single benchmark placement with no financial figures attached rarely moves the share price on its own, and fourth in a field of over 270 is still near the top. There are no fresh technical signals, so the picture rests entirely on the news side; where chart evidence and fundamentals would normally be weighed against each other, the news side carries the call here. That makes the strongly bearish label fragile in both directions. One stronger benchmark showing, a partnership or a positive pipeline readout could soften it quickly. For now, the balance of what is known leans bearish, and readers should treat the signal as a reflection of positioning doubts rather than of any new financial damage.
Frequently asked questions about Recursion Pharmaceuticals
What happened with the OpenADMET challenge, and why does it matter?
OpenADMET ran a blind challenge testing how well AI models predict CYP enzyme inhibition, an important step in judging drug safety. Results announced on November 6 placed Recursion fourth out of more than 270 eligible participants, behind winner Inductive and third-place NVIDIA. Because Recursion markets itself as a leader in AI-driven drug discovery, finishing behind specialised rivals in a public benchmark is a modest negative signal for its competitive positioning, even though it carries no direct financial figures.
Does this benchmark result hurt Recursion's revenue or pipeline?
Not directly. The announcement contains no revenue or guidance impact, and the analysis treats it as a one-off competitive data point. Benchmark placements matter mainly for perception: they influence how investors and potential partners judge the quality of the company's AI platform. A fourth-place finish in a field of more than 270 is still near the top, so the negative signal is real but modest, and it may well fade without leaving a lasting mark on the share price.
What would change the bearish picture for Recursion?
The bearish view currently rests on news sentiment rather than chart signals, so it is sensitive to fresh information. A stronger showing in a future benchmark, a new partnership, positive pipeline progress or any concrete financial news could soften or reverse it. Because there are no active technical signals to confirm or contradict the news-driven lean, the next company-specific announcement carries unusually large weight in shaping the direction from here.
Why does US inflation data matter for a stock like Recursion?
The upcoming CPI releases set the macro backdrop for the whole market rather than pointing in a fixed direction for this stock. High-impact inflation figures move interest-rate expectations, and shifts in those expectations tend to sway risk appetite for the broader equity market. For a name whose current narrative is already under pressure, a sharp market-wide move around the CPI report could amplify or mask the effect of its own news, so it is the main external event to watch in the coming days.
📝 Overview Generated automatically
RXRX has been the subject of 2 signals across 2 articles in the last 365 days. Sentiment skews Bearish (50%).
Breakdown: 1 bullish, 1 bearish, 0 neutral.
Most-cited catalysts: OpenADMET CYP Direct Inhibition Blind Challenge results announced Nov. 6, 2026 with Recursion ranked fourth (1×). Most-cited risk factors: Benchmark placement is a one-off result with no revenue or guidance impact stated (1×), Over 270 participants were ranked, so a fourth-place finish is still near the top of a large field (1×).
Related assets
Same category or comparable signal picture — each card opens the full cockpit.